<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>GI Signals - Pancreas/Biliary</title><link>https://siftingsignal.com/gisignals/</link><description>Pancreas/Biliary papers worth knowing in GI this week. A SiftingSignal publication.</description><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://siftingsignal.com/gisignals/feed/pancreas-biliary.xml" rel="self" type="application/rss+xml"/><item><title>Ciliogenic pancreatopathy reveals a link between ciliopathies and exocrine pancreatic disease.</title><link>https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42613169</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42613169</guid><pubDate>Mon, 24 Aug 2026 19:12:09 +0000</pubDate><description>Gut. Patients with ciliopathy-causing mutations HNF1B or NPHP3, particularly those with kidney disease and pediatric-onset pancreatic disease, develop pancreatic fat accumulation (adipopancreatosis) detectable on MRI; clinical significance and impact on pancreatic function or renal outcomes remain unclear.</description></item><item><title>Timing of cholecystectomy after acute biliary pancreatitis: Impact of disease severity and biological sex.</title><link>https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42613244</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42613244</guid><pubDate>Mon, 24 Aug 2026 19:12:09 +0000</pubDate><description>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. For mild biliary pancreatitis, early cholecystectomy during index admission remains safe; counsel male patients about anticipated surgical complexity and intensive care utilization. For moderate/severe biliary pancreatitis, particularly in female patients, consider interval cholecystectomy to reduce intensive care duration and hospitalization length. Use disease severity and sex to individualize timing strategies and set realistic expectations for recovery resource needs.</description></item><item><title>Chemotherapy for Unresectable Pancreatic Cancer Complicated by Disseminated Intravascular Coagulation: A Retrospective Cohort Study.</title><link>https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42616029</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42616029</guid><pubDate>Mon, 24 Aug 2026 19:12:09 +0000</pubDate><description>Pancreas. Recognize tumor-related DIC in APC as a marker of extremely poor prognosis (median 1.3 months versus 10.4 months without DIC). Infection-related DIC outcomes differ from both but specific survival not quantified in this series. In patients with tumor-related DIC, chemotherapy with anticoagulation or antifibrinolytic support achieved transient DIC resolution in 4 of 8 patients in this series; however, resolution was temporary and recurrence occurred with tumor progression. Its independent contribution to improved survival requires cautious interpretation. This is exploratory evidence from a small retrospective cohort; selection criteria not detailed.</description></item><item><title>Prognostic Utility of the Cachexia Index in Resectable and Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy.</title><link>https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42623055</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42623055</guid><pubDate>Mon, 24 Aug 2026 19:12:09 +0000</pubDate><description>Pancreas. S-CXI may identify high-risk resectable pancreatic cancer patients who could benefit from intensified perioperative multidisciplinary care. However, this retrospective study does not test interventions to improve outcomes in high-risk patients; prospective validation and trials of outcome-improvement strategies are needed before routine clinical use.</description></item><item><title>Emerging Issue - Fatty Pancreas in Pancreatic Cystic Neoplasms: Results of a Matched Case-Control Study.</title><link>https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42627603</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42627603</guid><pubDate>Mon, 24 Aug 2026 19:12:09 +0000</pubDate><description>Digestive diseases and sciences. Fatty pancreas does not appear to independently increase pancreatic cystic neoplasm risk based on this study. Current PNCL risk stratification using established imaging features and CA 19-9 levels should not change; fatty pancreas should not be incorporated as a risk factor at this time. The non-significant tail trend warrants further investigation but does not yet support modified surveillance or management.</description></item><item><title>Long-term impact of acute pancreatitis on patients&#x27; quality of life: a multi-center prospective study in Japan.</title><link>https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42633599</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42633599</guid><pubDate>Mon, 24 Aug 2026 19:12:09 +0000</pubDate><description>Journal of gastroenterology. Assess physical and social function at 3 months in acute pancreatitis survivors (measurement instruments detailed in source), emphasizing females and those with higher initial disease severity. Patients with lower physical component scores warrant intensive psychosocial support. Important: At 12 months, younger age paradoxically predicts incomplete recovery-do not assume standard age-based recovery trajectories.</description></item><item><title>Pancreatic exocrine function and morphology following prior malnutrition in Asian and African cohorts: A multi-cohort study.</title><link>https://siftingsignal.com/gisignals/2026-W34/#card-pmid-42595122</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W34/#card-pmid-42595122</guid><pubDate>Thu, 20 Aug 2026 18:40:03 +0000</pubDate><description>The American journal of clinical nutrition. Do not screen for exocrine pancreatic insufficiency based on malnutrition history alone. Although pancreatic morphology changes persist in malnutrition survivors (larger pancreases in adults, smaller in children when adjusted for body weight), FE-1-based exocrine function is not significantly impaired decades after malnutrition. This refutes prior famine-study concerns and suggests EPI in these populations is driven by other factors.</description></item><item><title>The Clinicopathological Characteristics and Prognosis of Cholangiolocarcinoma: A Multicenter Study With a Central Pathology Review.</title><link>https://siftingsignal.com/gisignals/2026-W34/#card-pmid-42598877</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W34/#card-pmid-42598877</guid><pubDate>Thu, 20 Aug 2026 18:40:03 +0000</pubDate><description>Journal of hepato-biliary-pancreatic sciences. For patients with pathologically confirmed CLC (≥80% ductular iCCA with apical EMA positivity) being evaluated for surgical management, the favorable long-term outcomes in resected patients (median OS 10.8 years, 10-year survival 73.7%) compared to small-duct/large-duct-type iCCA with ductular configuration support optimistic prognostic counseling and prioritization for surgical evaluation in candidates deemed resectable.</description></item><item><title>Association of subcutaneous adiposity with survival outcomes in advanced biliary tract cancer treated with gemcitabine, cisplatin, and immune checkpoint inhibitor.</title><link>https://siftingsignal.com/gisignals/2026-W34/#card-pmid-42599292</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W34/#card-pmid-42599292</guid><pubDate>Thu, 20 Aug 2026 18:40:03 +0000</pubDate><description>Journal of gastroenterology. A prognostic association identified in a small retrospective cohort; does not guide treatment selection, monitoring, or counseling beyond current practice. Potential utility for medical oncologists in risk stratification and future trial design, but not actionable for general gastroenterology practice.</description></item><item><title>Bile Leak Grade Is Associated with Healing Time and Subsequent Biliary Stricture After Liver Transplantation.</title><link>https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42570076</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42570076</guid><pubDate>Thu, 20 Aug 2026 21:35:47 +0000</pubDate><description>Digestive diseases and sciences. Leak grade predicts stricture risk: 94.7% for high-grade versus 0% for low-grade within 12 months. Use leak grade to risk-stratify and consider intensifying endoscopic surveillance in high-grade leaks, pending prospective validation of specific surveillance protocols.</description></item><item><title>The Global Immune-Nutrition-Inflammation Index (GINI) in Acute Pancreatitis Severity Assessment: A Comparative Study.</title><link>https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42570998</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42570998</guid><pubDate>Thu, 20 Aug 2026 21:35:47 +0000</pubDate><description>Digestive diseases and sciences. GINI shows promise for early severity stratification in acute pancreatitis, with a high negative predictive value (92% NPV) for excluding moderate-severe disease. Clinical implementation requires the full paper to clarify the index&#x27;s calculation methodology. This single-center retrospective study requires prospective multicenter validation before adoption into routine practice.</description></item><item><title>Pancreatic exocrine function and morphology following prior malnutrition in Asian and African cohorts: A multi-cohort study.</title><link>https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42595122</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42595122</guid><pubDate>Thu, 20 Aug 2026 21:35:47 +0000</pubDate><description>The American journal of clinical nutrition. Do not screen for exocrine pancreatic insufficiency based on malnutrition history alone. Although pancreatic morphology changes persist in malnutrition survivors (larger pancreases in adults, smaller in children when adjusted for body weight), FE-1-based exocrine function is not significantly impaired decades after malnutrition. This refutes prior famine-study concerns and suggests EPI in these populations is driven by other factors.</description></item><item><title>Association of subcutaneous adiposity with survival outcomes in advanced biliary tract cancer treated with gemcitabine, cisplatin, and immune checkpoint inhibitor.</title><link>https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42599292</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42599292</guid><pubDate>Thu, 20 Aug 2026 21:35:47 +0000</pubDate><description>Journal of gastroenterology. A prognostic association identified in a small retrospective cohort; does not guide treatment selection, monitoring, or counseling beyond current practice. Potential utility for medical oncologists in risk stratification and future trial design, but not actionable for general gastroenterology practice.</description></item><item><title>Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group.</title><link>https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42601286</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W33/#card-pmid-42601286</guid><pubDate>Thu, 20 Aug 2026 21:35:47 +0000</pubDate><description>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. Calculate SIRI from baseline CBC in newly diagnosed metastatic pancreatic cancer for prognostic stratification. Low values (≤2.3) predict longer survival (14.0 vs 9.2 months median OS), superior progression-free survival (5.9 vs 3.9 months), and higher chemotherapy response (37% vs 25%). Use this objective, CBC-derived marker to inform prognostic counseling and discussions about expected clinical course.</description></item><item><title>Longitudinal Study of Comorbidities and Clinical Outcomes in Persons With Pancreatic Disease Using Electronic Health Records.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-41910023</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-41910023</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Pancreas. No clinical action yet: this is an epidemiological study identifying associations, not interventions or diagnostic criteria.</description></item><item><title>Prevalence of Sarcopenia in Children Undergoing Total Pancreatectomy With Islet Autotransplantation (TPIAT) and Implications for Short-Term Surgical Outcomes.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-41930725</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-41930725</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Pancreas. No clinical action yet: sarcopenia prevalence in pediatric TPIAT patients is high but does not predict short-term surgical outcomes. Further research is needed to understand the clinical implications of the association between preoperative pain frequency and sarcopenia.</description></item><item><title>The Effect of Different Lipid-Lowering Methods on the Clinical Outcomes of Hypertriglyceridemic Acute Pancreatitis.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-41944357</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-41944357</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Pancreas. Consider sequential insulin therapy for HTGP patients prioritizing faster diet resumption and cost savings, but monitor closely for hypoglycemia. Lipid-lowering drugs remain an alternative if hypoglycemia risk is a concern.</description></item><item><title>Dietary Patterns Following an Episode of Acute Pancreatitis: A Post Hoc Analysis From the PAPPEI Multicenter, Prospective Study.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42047302</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42047302</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Pancreas. Consider assessing dietary patterns in patients after acute pancreatitis, as poorer baseline diet (lower scores) correlates with worse outcomes (recurrent AP, weight loss, persistent symptoms). No clinical action yet: this is observational and does not test dietary interventions.</description></item><item><title>Pancreatic MRI Findings in High-Risk Individuals Compared With Matched Average-Risk Individuals.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42112592</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42112592</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Pancreas. Consider that PCLs are more common but smaller in HRI (familial pancreatic cancer or pathogenic germline variant carriers) than in ARI, but no difference in worrisome features was found. No clinical action yet: this is a descriptive study without longitudinal malignancy data.</description></item><item><title>Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42348838</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42348838</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Pancreas. No clinical action yet: this is a foundational cohort study establishing infrastructure and preliminary data for future CP research.</description></item><item><title>Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42494243</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42494243</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Liver international : official journal of the International Association for the Study of the Liver. CDKN2A/BAP1 mutations may identify patients with poorer pemigatinib response, but current SOC does not yet support altering therapy based on these findings. Further validation is needed.</description></item><item><title>From guidelines to precision care: How contemporary evidence is transforming IPMN management.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42527223</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42527223</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Consider personalized IPMN management based on subtype (main-duct/mixed vs. branch-duct), cyst stability, growth rate, age, and overall health. Avoid unnecessary surveillance for low-risk branch-duct IPMNs.</description></item><item><title>Patterns of progression and efficacy of immune checkpoint inhibitors in unresectable, recurrent, or metastatic cholangiocarcinoma: A real-world study.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42538239</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42538239</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. In CCA patients on ICIs with oligo-progression, local plus systemic therapy showed a non-significant trend toward better OS than systemic therapy alone (28.9 vs 15.8 months, p=0.062); further evidence is needed before recommending local therapy routinely. Monitor CA199 (≥35 U/ml predicts worse outcomes) and assess for lung/LN/RPLN metastases.</description></item><item><title>Hospital Volume and Operative Mortality in Pancreaticoduodenectomy and Hepatectomy: Analysis of the National Clinical Database in Japan.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42544738</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42544738</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Journal of hepato-biliary-pancreatic sciences. Refer patients undergoing pancreaticoduodenectomy or advanced hepatectomy to centers performing ≥50 advanced HBP procedures annually when feasible, as mortality is lower.</description></item><item><title>Solid pancreatic lesions in young patients (&lt;40 years): Should we be worried about? Lessons from 4 years of EUS guided FNB in a tertiary center.</title><link>https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42547361</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42547361</guid><pubDate>Thu, 06 Aug 2026 18:00:11 +0000</pubDate><description>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. In young patients (&lt;40) with SPLs, perform EUS-guided FNB to rule out PDAC, especially if hypovascular lesions, MPD dilation, or CBD dilation are present. NET (44.6%) and solid pseudopapillary neoplasms (24.6%) were more common diagnoses in this cohort.</description></item><item><title>The degree of obesity correlates with the severity of acute pancreatitis: An international multicenter cohort analysis of 2244 patients.</title><link>https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42521531</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42521531</guid><pubDate>Thu, 30 Jul 2026 22:01:39 +0000</pubDate><description>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. Recognize that obesity severity correlates with AP complications; no specific clinical actions beyond standard monitoring are currently evidence-based.</description></item><item><title>From guidelines to precision care: How contemporary evidence is transforming IPMN management.</title><link>https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42527223</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42527223</guid><pubDate>Thu, 30 Jul 2026 22:01:39 +0000</pubDate><description>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Consider personalized IPMN management based on subtype (main-duct/mixed vs. branch-duct), cyst stability, growth rate, age, and overall health. Avoid unnecessary surveillance for low-risk branch-duct IPMNs.</description></item><item><title>Associations of abnormal blood lipid levels with hospitalization cost and disease severity in patients with hyperlipidemic pancreatitis: a retrospective cohort study.</title><link>https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42482176</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42482176</guid><pubDate>Sat, 25 Jul 2026 22:16:33 +0000</pubDate><description>BMC gastroenterology. Consider triglyceride and total cholesterol levels as risk indicators in acute hyperlipidemic pancreatitis - higher levels identify patients at increased risk for ICU transfer and complications. This observational association does not establish that more aggressive acute lipid management improves outcomes; continue guideline-directed care for acute pancreatitis and chronic lipid management.</description></item><item><title>Clinical Trial: Multi-Strain Probiotic Improves Bile Acid Profile, Microbiome, and Metabolomic Parameters in Patients With History of Bile Acid Malabsorption-A Randomized, Controlled Trial.</title><link>https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42487516</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42487516</guid><pubDate>Sat, 25 Jul 2026 22:16:33 +0000</pubDate><description>Alimentary pharmacology &amp; therapeutics. Do not recommend this probiotic for BAM management based on current evidence; the 3-week trial showed no symptom improvement despite biochemical changes. The microbiota-modifying effects suggest a plausible mechanism, but clinical utility would require longer trials with validated symptom or quality-of-life endpoints before bedside use.</description></item><item><title>Association of early crystalloid type with mortality and costs in acute pancreatitis: a nationwide cohort study.</title><link>https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42489684</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42489684</guid><pubDate>Sat, 25 Jul 2026 22:16:33 +0000</pubDate><description>Journal of gastroenterology. For early crystalloid resuscitation in acute pancreatitis admitted to general medical wards, prefer balanced Ringer&#x27;s solutions over normal saline based on this observational evidence of lower mortality and reduced costs; applicability to intensive care or more severely ill patients is not defined in this study.</description></item><item><title>An ABC approach for preoperative staging in perihilar cholangiocarcinoma An international multicenter cohort study.</title><link>https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42497926</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42497926</guid><pubDate>Sat, 25 Jul 2026 22:16:33 +0000</pubDate><description>Journal of hepatology. Consider avoiding curative-intent resection in pCCA patients with an ABC score of 3 (tumor size ≥25 mm, CA19-9 ≥500 U/mL, WHO PS ≥1) due to high mortality and recurrence risks, but note this is based on retrospective data.</description></item><item><title>Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study.</title><link>https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42498621</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42498621</guid><pubDate>Sat, 25 Jul 2026 22:16:33 +0000</pubDate><description>Gut. Be aware that pancreatic cancer risk is elevated in new-onset diabetes (NOD), particularly with higher initial treatment intensity (aHRs 3.01, 4.32, 5.60 for no antidiabetics, oral antidiabetics, insulin) or rapid escalation within 6 months (aHR 6.50 vs stable). This association is strongest within 3 years of NOD diagnosis. No specific screening protocol is validated in this population.</description></item><item><title>Molecular Subtypes of Cholangiocarcinoma and their Translational Implications.</title><link>https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42442510</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42442510</guid><pubDate>Sat, 18 Jul 2026 20:04:34 +0000</pubDate><description>Gastroenterology. Consider molecular profiling (e.g., FGFR2 fusions, IDH1/2 mutations) for intrahepatic cholangiocarcinoma patients to identify potential targeted therapy options. No clinical action yet for other subtypes or mechanisms discussed, as this is a review of existing evidence.</description></item><item><title>Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database.</title><link>https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42463583</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42463583</guid><pubDate>Sat, 18 Jul 2026 20:04:34 +0000</pubDate><description>Journal of gastroenterology. Consider adjuvant therapy for PDAC patients over 80 after pancreatectomy if clinically eligible (ECOG/organ function permitting), as it is associated with a 7-month survival benefit. Neoadjuvant treatment did not demonstrate benefit in this cohort.</description></item><item><title>pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer.</title><link>https://siftingsignal.com/gisignals/2026-W26/#card-pmid-41941588</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W26/#card-pmid-41941588</guid><pubDate>Thu, 09 Jul 2026 16:47:07 +0000</pubDate><description>Pancreas. Use pRECIST criteria for consistent response assessment in clinical trials testing pancreatic cancer therapies, particularly in neoadjuvant settings, as it requires CT and PET imaging for combined size and metabolic evaluation.</description></item><item><title>Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial.</title><link>https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42386316</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42386316</guid><pubDate>Thu, 09 Jul 2026 16:47:07 +0000</pubDate><description>BMJ (Clinical research ed.). For resectable pancreatic or periampullary disease in eligible patients at high-volume centers, consider robotic pancreatoduodenectomy (RPD) as a non-inferior alternative to open surgery (OPD) for potentially faster recovery and reduced complications.</description></item><item><title>Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.</title><link>https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42402265</link><guid isPermaLink="true">https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42402265</guid><pubDate>Thu, 09 Jul 2026 16:47:07 +0000</pubDate><description>Journal of hepatology. Durvalumab added to gemcitabine-based chemotherapy is already standard first-line care for advanced biliary tract cancer (TOPAZ-1); TOURMALINE supports its safety and efficacy across a broader range of gemcitabine-based regimens rather than establishing a new, unadopted therapy.</description></item></channel></rss>